$AGEN News

Last published 6d ago

6d agoAGENAGENUS INC - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
6d agoAGENRodman & Renshaw Fireside Chat | November 2026 - AGENUS INCEarnings Call Transcriptsmany more patients starting when we do our first enrollment for the Robin trial, which we anticipate in the next few months. Great. And I'm Robin Taylor. I'm the chief commercial officer. I've been with the Gen S for a l
2w agoAGENAgenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026Business WireThe cohort met its primary endpoint of major pathologic response, with 83% of patients having little or no cancer remaining at surgery in a high-risk, locally advanced population Side effects were mostly mild and
2w agoAGENAgenus to Provide Third Quarter 2026 Financial Report and Development UpdateBusiness WireAgenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Company will release its third quarter 2026 financial results before the market opens on Thursday,
3w agoAGENCHARDAN HEALTHCARE CONFERENCE – 10 YEARS OF DISRUPTIVE INNOVATION - AGENUS INCEarnings Call TranscriptsFantastic. Okay, so we're going to be dealing with some shot clock issues here. That last session with Dr. Schlechter was supposed to be 25 minutes, 30 minutes. We cut that pretty short. But since Dr. Shlechter is very f
1mo agoAGENAgenus to Participate in Chardan’s 10th Annual Healthcare Investor ConferenceBusiness WireAgenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that Zack Armen, Head of Corporate Development and Investor Relations, will participate in a fireside chat and one-on-one investor
1mo agoAGENArmenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal CancerBusiness WireBotvymo® (botensilimab) and Evamplix® (balstilimab) receive separate approvals for use in combination Armenia is the first country to approve marketing authorization of BOT+BAL, following a rigorous review of
1mo agoAGENAgenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026Business WireSurvival estimate remained at 48% between years two and three, extending evidence of durable benefit Results observed in heavily pretreated, difficult-to-treat population that received a median of four prior lines
1mo agoAGENAgenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026Business WireAgenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with
2mo agoAGENA Conversation on Immunotherapy Before Surgery with Benjamin Schlechter, MD, DFCI - AGENUS INCEarnings Call TranscriptsHello Ben. We're joined today with Dr. Ben Schlechter, who is a senior physician at Dana Farber Cancer Institute. And we've had the privilege of working with Dr Schlechter for a number of years now, particularly in the c
2mo agoAGENAgenus Stakeholder Webcast | September 2026 - AGENUS INCEarnings Call TranscriptsGood afternoon, everyone, and thank you for joining us today. My name is Stephanie Nakar. I'm Chief Communications Officer here at Agenis, and I want to welcome you to our September Stakeholder Webcast. Joining me today
2mo agoAGENAgenus Stakeholder Webcast - AGENUS INCEarnings Call TranscriptsGood afternoon, everyone, and thank you for joining us today. My name is Stephanie Nakar. I'm Chief Communications Officer here at Agenis, and I want to welcome you to our September Stakeholder Webcast. Joining me today
2mo agoAGENAgenus Stakeholder Webcast | September 2026 - AGENUS INCEarnings Call TranscriptsGood afternoon, everyone, and thank you for joining us today. My name is Stephanie Nakar. I'm Chief Communications Officer here at Agenis, and I want to welcome you to our September Stakeholder Webcast. Joining me today
2mo agoAGENAgenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026Business WireAgenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that a poster evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab
2mo agoAGENAgenus to Participate in Upcoming September Investor ConferencesBusiness WireAgenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Ph.D., Chief Commercial Officer, and Zack Armen, Head of Corporate Development and Investor Relations, will
2mo agoAGENAgenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming MechanismBusiness WireMature 123 patient analysis reports 21.2-month median overall survival and 33% three-year overall survival in heavily pretreated MSS mCRC without active liver metastases Responses observed in tumors with low tumor
2mo agoAGENAgenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon CancerBusiness WireNo colorectal cancer recurrences observed at updated median follow-up of 32.2 months in NEST-1 and 23.5 months in NEST-2 In pMMR/MSS tumors, neoadjuvant BOT+BAL achieved 59% pathologic response, including 41% major
2mo agoAGENHow to Improve the New Cancer Vaccine? | Conversations in Action - AGENUS INCEarnings Call TranscriptsFor the first time we've cracked a way to harness the immune system to prevent cancer from coming back. No universal vaccine against cancer you think? Now you can actually start to change the DNA and that is both excitin
2mo agoAGENHOW TO IMPROVE THE NEW CANCER VACCINE? | CONVERSATIONS IN ACTION - AGENUS INCEarnings Call TranscriptsFor the first time we've cracked a way to harness the immune system to prevent cancer from coming back. No universal vaccine against cancer you think? Now you can actually start to change the DNA and that is both excitin
3mo agoAGEN INKTAgenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon CancerBusiness WirePreviously announced oversubscribed $85 million private placement, with up to an additional $255 million in potential proceeds from milestone-aligned warrants, supports ROBBIN execution ROBBIN addresses
3mo agoAGENAgenus to Provide Second Quarter 2026 Financial Report and Development UpdateBusiness WireAgenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its second quarter 2026 financial results before the market opens on Thursday, August 6,
3mo agoAGENAgenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026Business WireAgenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials evaluating botensilimab and balstilimab (BOT+BAL) have been accepted for poster
4mo agoAGENAgenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon CancerBusiness Wire$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in
4mo agoAGENAgenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026Business WireFully enrolled 123-patient Phase 1b cohort demonstrated 21.2-month median overall survival, 33% three-year overall survival, and a survival curve plateau beyond two years Data presented in a heavily pretreated
4mo agoAGENAgenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026Business WireData reflect an additional year of follow-up from the 123-patient cohort in the Phase 1b study Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that three-year survival data from
5mo agoAGENAgenus Announces Virtual 2026 Annual Shareholders MeetingBusiness WireAgenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:00 a.m. ET on June 16, 2026, and will be conducted in a virtual format
5mo agoAGEN INKTAgenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026Business WireFirst presentation of BOT+BAL melanoma data in heavily pretreated patients whose disease had resisted prior checkpoint therapy and who had poor-risk disease features In the overall BOT+BAL treated population, median
5mo agoAGEN INKTAgenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRCBusiness WireNoetik's TARIO-2 platform analyzed routine pretreatment H&E images from 113 BOT+BAL-treated patients and identified spatial tumor microenvironment patterns associated with response and survival In a
6mo agoAGEN INKTAgenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver CancerBusiness WirePublished prospective cohort showed durable responses and manageable safety in patients with HCC following prior immunotherapy Median overall survival of 12.3 months in a heavily pretreated population with poor
6mo agoAGEN INKTAgenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 DevelopmentBusiness WireAuthorized access interest continues to expand across regions Phase 3 BATTMAN trial commenced patient enrollment in April 2026, advancing BOT+BAL into pivotal evaluation Zydus collaboration closed in January,
6mo agoAGENAgenus to Provide First Quarter 2026 Financial Report and Corporate UpdateBusiness WireAgenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its first quarter 2026 financial results before the market opens on Monday, May 11, 2026. Agenus plans
6mo agoAGENAgenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026Business WireFour abstracts accepted across melanoma, colorectal cancer, and translational research Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that four abstracts highlighting botensilimab
6mo agoAGENAgenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access ProgramsBusiness WirePartnership enables timely access to botensilimab plus balstilimab through France's government-reimbursed Autorisation d'Accès Compassionnel (AAC) pathway and paid named-patient programs (NPP) in select
6mo agoAGENAgenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal CancerBusiness WireFirst study combining botensilimab (BOT) and balstilimab (BAL) with agenT-797 in gastroesophageal cancer shows disease control rate (DCR) of 77% in patients and long-term survival beyond 20 months in a subset of
7mo agoAGENAgenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026Business WireStudy highlights novel multi-mechanistic immunotherapy combination in checkpoint-refractory disease Data expected to inform immune modulation, treatment sequencing, and durability of response across hard-to-treat
7mo agoAGENAgenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal CancerBusiness WireA Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer Cases Colorectal Cancer Has Become the Leading Cause of Cancer-related Death
7mo agoAGENAgenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient AccessBusiness WireWebcast on Tuesday, March 31, 2026, at 4:30 p.m. ET Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its March Stakeholder Webcast focused on continued progress of its
7mo agoAGENAgenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal CancerBusiness WireA novel, chemo-sparing strategy (BBoPCO): introducing BOT+BAL in 1L MSS mCRC to extend survival and reduce use of cytotoxic chemotherapy Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that
8mo agoAGENAgenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues RecognizedBusiness WireEarly access programs expand globally: 200+ physician inquiries across 30+ countries; $4.2M in initial program revenue recognized CRC leads BOT+BAL clinical development: 42% two-year overall survival and ~21-month
8mo agoAGENAgenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing NeedsBusiness WireWork orders for key CMC and production activities activate first contingent payment as global demand expands across clinical and paid compassionate access programs Agenus Inc. (NASDAQ:AGEN), a leader in
8mo agoAGENAgenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate UpdateBusiness WireAgenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its fourth quarter and year-end 2025 financial results before the market opens on Monday, March 16,
8mo agoAGENAgenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BALBusiness WireIntegrated analysis of systemic inflammation and tumor immune features identifies biologically distinct patient subgroups with differential survival outcomes, outperforming conventional biomarkers Agenus Inc.
9mo agoAGENAgenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold TumorsBusiness WireAgenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that new translational and clinical biomarker analyses from its botensilimab (BOT) immunotherapy program have been accepted for poster presentation
9mo agoAGENAGENUS Webcast January 2026 | Access to Acceleration: BOT+BAL Global Momentum Entering 2026AGENUS INCEarnings Call TranscriptsThis program is designed to reflect the full arc of momentum we are seeing globally, from manufacturing and execution to expanded patient access, to the clinical evidence needed to support regulatory pathways. You'll hea
9mo agoAGENAGENUS WEBCAST JANUARY 2026 | ACCESS TO ACCELERATION: BOT+BAL GLOBAL MOMENTUM ENTERING 2026 - AGENUS INCEarnings Call TranscriptsThis program is designed to reflect the full arc of momentum we are seeing globally, from manufacturing and execution to expanded patient access, to the clinical evidence needed to support regulatory pathways. You'll hea
10mo agoAGENZydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.PR NewswireZydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as "Zydus") is an innovation-led life-sciences company with...
10mo agoAGENFrance Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue SarcomasBusiness WireUpdated national AAC protocol supports hospital-based, fully-reimbursed compassionate access across three solid tumor settings Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that
10mo agoAGENAgenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITCBusiness WireDeep and durable responses observed in a heavily pretreated, historically immunotherapy-resistant population Findings reinforce the broad, pan-tumor activity of BOT+BAL across immunologically "cold" cancers Agenus
11mo agoAGEN CRDF EXEL GILD+1GI Cancer Immunotherapy Breakthroughs Signal New Treatment EraGlobeNewswireVANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA approved the first perioperative immunotherapy for early gastric and gastroesophageal junction cancers last
11mo agoAGENAgenus December 2025 Stakeholder Engagement Webcast - AGENUS INCEarnings Call Transcripts2025 Stakeholder Webcast, where we bring together scientific leaders, clinicians, and patient voices to discuss the progress and global momentum surrounding the Bop-Bell Immunotherapy Program. Before we begin, a quick re